TESARO Inc (TSRO) Given Consensus Rating of “Buy” by Analysts

TESARO Inc (NASDAQ:TSRO) has been given a consensus recommendation of “Buy” by the twenty-three ratings firms that are currently covering the firm, MarketBeat reports. Two analysts have rated the stock with a sell recommendation, six have given a hold recommendation and fifteen have given a buy recommendation to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $106.33.

A number of research firms recently weighed in on TSRO. Robert W. Baird restated a “hold” rating on shares of TESARO in a research note on Tuesday, April 24th. BidaskClub cut shares of TESARO from a “sell” rating to a “strong sell” rating in a research note on Friday, April 20th. Lake Street Capital set a $120.00 target price on shares of TESARO and gave the company a “buy” rating in a research note on Sunday, April 22nd. Argus decreased their price target on shares of TESARO from $154.00 to $110.00 and set a “buy” rating on the stock in a research note on Wednesday, May 2nd. Finally, Credit Suisse Group decreased their price target on shares of TESARO from $141.00 to $128.00 and set an “outperform” rating on the stock in a research note on Friday, May 4th.

In other TESARO news, Director Lawrence M. Alleva sold 7,142 shares of the business’s stock in a transaction on Tuesday, June 12th. The shares were sold at an average price of $43.11, for a total value of $307,891.62. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 33.70% of the stock is owned by insiders.

A number of hedge funds have recently made changes to their positions in TSRO. Millennium Management LLC increased its holdings in shares of TESARO by 151.7% in the 4th quarter. Millennium Management LLC now owns 304,549 shares of the biopharmaceutical company’s stock worth $25,238,000 after buying an additional 183,552 shares during the last quarter. Macquarie Group Ltd. increased its holdings in shares of TESARO by 36.6% in the 4th quarter. Macquarie Group Ltd. now owns 115,354 shares of the biopharmaceutical company’s stock worth $9,559,000 after buying an additional 30,895 shares during the last quarter. NJ State Employees Deferred Compensation Plan increased its holdings in shares of TESARO by 37.5% in the 1st quarter. NJ State Employees Deferred Compensation Plan now owns 11,000 shares of the biopharmaceutical company’s stock worth $629,000 after buying an additional 3,000 shares during the last quarter. Commerzbank Aktiengesellschaft FI bought a new stake in shares of TESARO in the 1st quarter worth about $344,000. Finally, Alps Advisors Inc. increased its holdings in shares of TESARO by 21.0% in the 1st quarter. Alps Advisors Inc. now owns 72,938 shares of the biopharmaceutical company’s stock worth $4,168,000 after buying an additional 12,676 shares during the last quarter.

Shares of TESARO traded down $1.12, reaching $35.12, during trading hours on Friday, according to MarketBeat. 1,140,033 shares of the stock traded hands, compared to its average volume of 1,452,475. The company has a debt-to-equity ratio of 3.74, a quick ratio of 3.56 and a current ratio of 4.02. TESARO has a 52-week low of $34.54 and a 52-week high of $136.45. The stock has a market cap of $1.95 billion, a price-to-earnings ratio of -3.83 and a beta of 1.21.

TESARO (NASDAQ:TSRO) last released its earnings results on Thursday, May 3rd. The biopharmaceutical company reported ($2.98) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.56) by ($0.42). TESARO had a negative net margin of 193.42% and a negative return on equity of 177.92%. The firm had revenue of $49.74 million for the quarter, compared to analysts’ expectations of $56.34 million. During the same quarter last year, the firm posted ($2.55) EPS. The firm’s quarterly revenue was up 1520.2% compared to the same quarter last year. equities research analysts predict that TESARO will post -10.02 earnings per share for the current year.

About TESARO

Tesaro, Inc, an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. It offers ZEJULA (niraparib), an orally active and potent poly polymerase inhibitor for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; and VARUBI (rolapitant), a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting.

Featured Story: Price to Earnings Ratio (PE)

Analyst Recommendations for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply